NCT00678028

Brief Summary

Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2008

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

February 17, 2008

Completed
3 months until next milestone

First Posted

Study publicly available on registry

May 15, 2008

Completed
Last Updated

April 23, 2009

Status Verified

April 1, 2009

First QC Date

February 17, 2008

Last Update Submit

April 22, 2009

Conditions

Recurrent Urinary Tract Infections

Keywords

MBL, UTI

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

young women with recurrent UTI - study group and young women witout recurrent UTI - a control group

You may qualify if:

  • women above 18 years old.
  • premenopausal
  • recurrent UTI

You may not qualify if:

  • pregnancy
  • immunocompromised
  • active malignancy
  • HIV carrier

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ha'Emek Medical Center

Afula, 18101, Israel

Location

Biospecimen

Retention: SAMPLES WITH DNA

whole blood for genetic test and serum for MBL test

MeSH Terms

Conditions

Urinary Tract Infections

Condition Hierarchy (Ancestors)

InfectionsUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 17, 2008

First Posted

May 15, 2008

Study Start

February 1, 2008

Last Updated

April 23, 2009

Record last verified: 2009-04

Locations

IL(1)